SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Change PI Include Diagnostic to Include SAR COV-2 SBIR Phase II Remote Diagnostic Reader
Award last edited on: 2/6/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$1,875,000
Award Phase
2
Solicitation Topic Code
37
Principal Investigator
Kellie Honug Zhu

Company Information

NOWDiagnostics Inc

1200 Stewart Place
Springdale, AR 72764
   (479) 966-4530
   contact@nowdx.com
   www.nowdx.com
Location: Single
Congr. District: 03
County: Washingto

Phase I

Contract Number: 272201800055C-P00002-9999-1
Start Date: 9/29/2018    Completed: 1/31/2021
Phase I year
2020
Phase I Amount
$937,500
This proposal aims to further the development of an advanced telemonitoring and assessment platform that will enable the digital modernization of point-of-care diagnostics, disease surveillance, and healthcare screening for SARS-CoV-2.

Project Terms:
2019-nCoV; Advanced Development; COVID-19; Development; Diagnostic; digital; Disease Surveillance; Healthcare; Modernization; point-of-care diagnostics; screening

Phase II

Contract Number: 272201800055C
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2020
Phase II Amount
$937,500
The research proposed here will support seroprevalence studies of SARS CoV-2 antibodies by the use of a rapid test system that can perform multiplexed analyses from remote point-of-care sites and transmit results to a centralized database. A drop of blood is collected from the subject’s fingertip, inserted into the cassette, and the assay is initiated by pressing a button. The assay cassette is inserted into the smartphone reader to scan the unique bar code and process the results from the suspected COVID-19 blood specimen. The availability of these infection test results from distributed collection sites that can be uploaded to a centralized database will enhance infection control measures and the medical mission of first responders. The project will be performed by the continuing efforts of the research team from Now Diagnostics and the Geneva Foundation.